

Author Index for 1987

- Aalbers, C. 20:239, 22:127
Abrams, R. 20:57
Aceti, F. 20:207
Alessi, N.E. 20:275
Almay, B.G.L. 22:179
Amiri, Z. 21:221
Amsterdam, J.D. 20:325, 21:189
Angrist, B. 21:185
Ansseau, M. 22:193
Apelt, S. 22:303
Arató, M. 21:355
Arger, P. 21:189
Aryan, Z.S. 20:307
Asai, M. 21:49
Asnis, G. 20:79
- Balon, R. 21:359, 22:37, 22:263
Barchas, J.D. 21:1, 22:21
Barksdale, C. 22:117
Bartkó, G. 22:221
Bartko, J.J. 20:165
Baumgartner, R. 20:33
Baxter, L.R., Jr. 21:237
Bellodi, L. 21:293
Benjamin, E. 22:257
Benkert, O. 20:177
Berchou, R. 21:359
Berenbaum, S.A. 20:57
Berg, L. 21:55
Berger, P.A. 20:47, 21:1, 22:21, 22:29
Berman, N. 20:1
Berman, S.R. 21:95
Berrettini, W.H. 22:141
Bigler, E.D. 22:91
Bochnik, H.J. 22:275
Boronow, J. 22:91
Borst, U. 22:331
Boulenger, J.-P. 21:247
Brambilla, F. 20:19
Breslau, N. 20:285
Brewerton, T.D. 21:213
Brochet, D.M. 21:267
Brody, D. 21:185
Brown, A. 22:261
Bruza, D. 22:261
Burns, E.M. 20:165, 22:229
Burrows, G.D. 22:43
Butters, N. 21:357
Byron, J.P., Jr. 20:261
- Calderon, M. 20:33
Calil, H.M. 21:337
Campeas, R. 22:89
- Candolfi, C. 20:19
Carpenter, W.T., Jr. 22:319
Carstens, M.E. 20:239, 22:127
Casper, R.C. 20:249
Cavagnini, F. 20:19
Cazzullo, C.L. 21:293
Cerfontaine, J.-L. 22:193
Chalton, D.O. 20:239, 22:127
Chamberlain, K.G. 20:199
Channabasavanna, S.M. 21:349
Charney, D.S. 21:33
Cherek, D.R. 21:257
Chrousos, G.P. 20:229
Climko, R. 20:261
Coccaro, E.F. 22:257
Codd, E.E. 22:61
Coffman, J.A. 22:229
Cohen, B.M. 20:107, 20:299
Cohen, M.R. 21:43
Cohen, R. 22:331
Cohn, B.S. 21:205
Cole, J.O. 20:143, 20:155
Comess, K.A. 20:13
Cooper, T.B. 20:313
Coromilas, J. 22:341
Coryell, W. 20:265
Coulter, M.E. 22:149
Cowley, D.S. 21:169
Csernansky, J.G. 20:47
- Dackis, C.A. 20:261
Dager, S.R. 20:13, 21:169
Davidson, M. 20:307
Davies, B.M. 22:213
Davies, M. 22:341
Davis, G.C. 20:285
Davis, J.M. 20:165, 22:265
Davis, K.L. 20:307, 22:257
Dawson, G. 22:117
Delis, D.C. 21:357
DeLisi, L.E. 20:69
Demeter, E. 21:355
Demisch, L. 22:275
De Ruyter, M. 21:323
de Villiers, A.S. 22:127
Dillon, D.J. 20:97, 21:205
Dilsaver, S.C. 20:275
di Rosa, M. 21:293
Dixon, K.N. 20:189
Dobben, G.D. 20:165
Doran, A.R. 21:23
Dose, M. 22:303
Drinka, P.J. 21:199

- Droba, M. 20:325
 Dugger, D. 21:123
 Dunner, D.L. 21:13, 21:169
 Dupont, R.M. 21:357
 Dysken, M. 20:165

 Ebstein, R.P. 21:221
 Edell, W.S. 20:129
 Emrich, H.M. 22:303
 Engelbrecht, A.H. 20:239
 Erlenmeyer-Kimling, L. 22:159

 Fairbanks, L. 21:237
 Falus, A. 21:355
 Faull, K.F. 21:1, 22:21
 Fiume, S. 20:207
 Foa, E.B. 21:123
 Foreman, P.J. 22:69
 Fraioli, F. 20:207
 Frajese, G. 20:207
 Franck, G. 22:193
 Frazer, A. 20:1
 French, M.A. 20:199
 Frick, K. 20:117
 Friedhoff, A.J. 21:185
 Fuentenebro, F. 22:283
 Fujita, H. 21:285, 22:81
 Fulgham, J.R. 21:359
 Fyer, A.J. 20:97, 21:23, 21:205, 22:341

 Gagiano, C.A. 20:239, 22:127
 Galderisi, S. 21:137
 Gambini, O. 21:293
 Garbutt, J.C. 21:307
 Garnett, D. 21:89
 Garvey, M.J. 20:183
 Gebhart, P. 22:275
 Geenen, V. 22:193
 Gelenberg, A.J. 20:107
 George, D.T. 21:213
 Georgi, K. 22:275
 Gerbaldo, H. 22:275
 Gershon, E.S. 20:69
 Gillin, J.C. 20:181, 21:357
 Giordani, A.B. 20:307
 Glenn, M. 21:307
 Glover, V. 22:111
 Gold, M.S. 20:261
 Gold, P.W. 20:229
 Goldin, L.R. 20:69
 Goldstein, S. 20:79
 Goodman, S.I. 22:291
 Gorman, J.M. 20:97, 21:23, 21:205, 22:371
 Gottesman, I.I. 22:159
 Grabowski, J. 22:261

 Graziosi, S. 20:207
 Griez, E.J.L. 20:87
 Gross, H.S. 22:69
 Grossman, A. 22:207
 Guthrie, S. 21:161
 Gutman, R. 21:43
 Guze, B.H. 21:237

 Halbreich, U. 20:79
 Hama, Y. 21:285
 Hanin, I. 22:49
 Harrison, W. 21:9
 Heinrichs, D.W. 22:319
 Heninger, G.R. 21:33
 Herczeg, I. 22:221
 Hesselink, J.R. 21:357
 Himmelhoch, J.M. 22:49
 Hobin, P. 21:323
 Hoch, C.C. 21:95, 21:111
 Hollander, E. 22:89
 Hollifield, M. 21:313
 Holsboer, F. 20:83, 20:177
 Houck, P.A. 21:95
 Hsiao, J.K. 22:69
 Huggins, T. 22:11
 Hyde, T.S. 21:169

 Innis, R.B. 21:33
 Invitti, C. 20:19
 Iio, M. 21:285, 22:81
 Irwin, M.R. 20:181, 22:283
 Ishii, T. 21:285, 22:81

 Jacobsen, F.M. 22:1
 James, S.P. 21:89
 Janicak, P.G. 22:265
 Javid, J.I. 20:249
 Jernigan, T.L. 21:357
 Jimerson, D.C. 21:213
 Joffe, R.T. 21:71
 Jordan, R.C. 21:63
 Judd, F.K. 22:43

 Kaku, H. 21:229
 Kalin, N.H. 22:117
 Kanba, S. 21:49
 Kang, B.J. 20:79
 Kärkkäinen, J. 21:151
 Kartakis, D. 20:221
 Kathol, M.H. 22:229
 Katon, W.J. 21:313
 Kaufmann, C.A. 20:337
 Kelly, T.H. 21:257
 Kemali, D. 21:137
 Kempler, S. 22:311

- Khan, A. 20:13
 Khanna, S. 21:349
 Kimber, N.M. 22:43
 King, R.J. 21:1, 22:29
 Kishimoto, H. 21:285, 22:81
 Kitamura, T. 21:49
 Klar, H. 22:257
 Klein, D.F. 20:97, 21:23, 21:205, 22:341
 Kleinman, J.E. 22:291
 Knopf, S. 22:49
 Knowles, J.B. 22:149
 Korpi, E.R. 20:337, 22:291
 Koslow, S.H. 20:1
 Kozak, M.J. 21:123
 Kruckeberg, T.W. 22:229
 Kupfer, D.J. 21:95, 21:111
 Kuwahara, H. 21:285, 22:81

 Laatikainen, T. 21:151
 Lacoste, V. 21:181
 Lajtha, A. 20:313
 Lampertico, M. 20:19
 Langlais, P.J. 20:143, 20:155
 Legros, J.-J. 22:193
 Lerbinger, J.E. 20:143, 20:155
 Lerer, B. 21:221
 Levin, A.P. 21:23
 Levy, A.B. 20:189
 Liebowitz, M.R. 20:97, 21:23, 21:205, 22:89, 22:341
 Linnoila, M. 20:229, 21:161
 Loosen, P.T. 21:307
 Lousberg, H. 20:87
 Lykouras, L. 21:277
 Lynch, J.J. 22:69

 Macciardi, F. 21:293
 MacLean, A. 22:149
 Maddock, R.J. 22:29
 Maes, M. 21:323
 Maggioni, M. 20:19
 Magnani, A. 20:207
 Maguire, K.P. 22:213
 Magyar, K. 21:355
 Maislin, G. 20:325
 Maj, M. 21:137
 Malliaras, D. 21:277
 Mallinger, A.G. 22:49
 Mandal, M.K. 20:317
 Marangos, P.J. 21:247
 Marder, L.R. 20:215
 Marder, S.R. 22:283
 Marinelli, D.L. 21:189
 Markianos, M. 20:221
 Markowitz, J.S. 21:9

 Marnela, K.M. 20:337
 Martin, J.V. 21:89
 Martin, P. 21:267
 Masuda, Y. 21:49
 Matsushita, M. 21:285, 22:81
 Matussek, N. 21:85
 Maylath, E. 22:221
 Mazziotta, J.C. 21:237
 McAllister, D.A. 21:63
 McAmis, W. 21:43
 McCauley, R.B. 22:37
 McGrath, P.J. 21:9
 McIntyre, I.M. 22:43
 Melia, E. 20:207
 Meltzer, H.Y. 22:99
 Mendelson, W.B. 21:89
 Meyer, J.S. 20:129
 Miller, M.M. 20:143
 Milton, J. 21:89
 Mintz, M. 22:311
 Miyauchi, T. 21:285
 Mohs, R.C. 20:307
 Moldin, S.O. 22:159
 Morris, J.C. 21:55
 Moscovich, D. 21:221
 Moses, J.A., Jr. 22:29
 Müller, E.E. 20:19
 Müller-Oerlinghausen, B. 20:117
 Murchison, A. 22:29
 Mykityn, V.V. 20:307

 Nakagawara, M. 21:85, 21:229
 Nasrallah, H.A. 21:303, 22:229
 Naukkarinen, H. 21:151
 Nemes, Z.C. 20:313
 Nerozzi, D. 20:207
 Nomura, Y. 21:285
 Norman, T.R. 20:199, 22:43
 Nurnberger, J.I., Jr. 22:141

 Ohno, S. 21:285, 22:81
 Orsulak, P.J. 20:183
 Oxenkrug, G.F. 22:37

 Palkovits, M. 21:355
 Pandey, G.N. 22:265
 Panerai, A.E. 20:19
 Papart, P. 22:193
 Patlak, C.S. 20:165
 Paul, S.M. 21:23
 Peabody, C.A. 21:1, 22:21
 Perel, J.M. 21:111
 Perri, M.G. 21:63
 Pettigrew, K.D. 20:165
 Phelps, M.E. 21:237

- Pickar, D. 20:229, 21:161, 22:91
 Pirozzi, R. 21:137
 Platt, S. 20:307
 Plutchik, R. 22:243
 Pohl, R. 21:359, 22:37, 22:263
 Post, R.M. 21:71, 22:11
 Prabucki, K. 20:285
 Prasad, A. 22:111

 Quitkin, F.M. 21:9

 Rabkin, J.G. 21:9
 Rai, A. 20:317
 Rainey, J.M. 21:359, 22:37
 Raisys, V. 20:13
 Rampling, R.P. 22:111
 Rauscher, F.P. 21:63
 Raz, N. 22:91
 Raz, S. 22:91
 Regier, D.A. 20:165
 Reynolds, C.F. III 21:95, 21:111
 Rimon, R. 21:151
 Robbins, D.R. 20:275
 Robinson, D. 21:257
 Rosenberg, S. 20:57
 Rosenthal, N.E. 22:1
 Roth, W.T. 22:29
 Rothschild, A.J. 20:143, 20:155
 Rotrosen, J. 21:185
 Rotter, A. 22:1
 Roy, A. 20:229, 21:161
 Roy-Byrne, P.P. 21:71
 Rubenstein, K. 22:257
 Rubin, E.H. 21:55
 Rubinow, D.R. 22:11
 Russell, V.A. 20:239, 22:127
 Ryan, J. 20:79

 Sacchetti, E. 21:293
 Sack, D.A. 21:89
 Sakellariou, G. 20:221
 Salem, N., Jr. 21:247
 Sali, L. 20:19
 Salminen, K. 21:151
 Salvati, A. 21:137
 Sandler, M. 22:111
 Sato, C. 21:285
 Sattin, A. 21:63
 Schatzberg, A.F. 20:143, 20:155
 Schildkraut, J.J. 20:155
 Schlemmer, R.F., Jr. 20:249
 Schmidt, H. 20:189
 Schweitzer, J. 21:185
 Secunda, S. 20:1
 Selin, C.E. 21:237

 Sershen, H. 20:313
 Sharpless, N. 20:79
 Shelton, S. 22:117
 Sherwood, P. 22:263
 Shima, S. 21:49
 Shimogawa, S. 21:229
 Siever, L.J. 22:257
 Sigal, M. 22:311
 Simmons-Alling, S. 22:141
 Simon, P. 21:267
 Sitaram, N. 22:261
 Skwerer, R.G. 22:1
 Smeraldi, E. 21:293
 Smith, R.C. 20:33
 Soubrie, P. 21:267
 Spoor, J. 21:151
 Stack, J.A. 21:95, 21:111
 Starace, F. 21:137
 Stefanis, C. 21:277
 Steiger, A. 20:177
 Steinberg, J.L. 21:257
 Steinman, R. 22:341
 Steketee, G. 21:123
 Stenman, U.-H. 21:151
 Stewart, J.W. 21:9
 Stieglitz, R.-D. 20:117
 Storandt, M. 21:55
 Sunderland, T. 20:299
 Surridge-David, M. 22:149
 Suy, E. 21:323
 Swann, A.C. 20:1
 Sweeney, D.R. 20:261

 Takahashi, R. 21:229
 Takazu, O. 21:285, 22:81
 Taljaard, J.J.F. 20:239, 22:127
 Tariot, P. 22:117
 Taylor, M.A. 20:57
 Tekes, K. 21:355
 Thase, M.E. 22:49
 Thiemann, S. 20:47
 Thienemann, M. 22:117
 Tiller, J.W.G. 22:213
 Timsit-Berthier, M. 22:193
 Tollefson, G.D. 20:183
 Tomer, R. 22:311
 Tóthfalusi, L. 21:355
 Tsichlakis, N. 20:221
 Tsukomo, T. 21:49
 Turkheimer, E. 22:91
 Turner, T.H. 22:207

 Uhde, T.W. 21:71, 21:247, 22:11
 Ulrich, G. 20:117
 Ur, E. 22:207


Valente, A. 21:137
van den Hout, M.A. 20:87
van der Molen, G.M. 20:87
van Praag, H.M. 22:243
Vassilopoulos, D. 21:277
Veith, R.C. 21:313
Villacres, E.C. 21:313
Vita, A. 21:293
Voeks, S.K. 21:199
Volavka, J. 20:313
von Frenckell, R. 22:193
von Knorring, L. 22:179
Voulgari, A. 21:277

Wagman, A.M.I. 22:319
Wagner, R. 21:89
Walker, R.F. 22:61
Warner, M.D. 22:21
Watanabe, A. 21:229
Wehr, T.A. 21:89
Weiler, S. 22:117
Weinberger, D.R. 20:337, 22:91
Wetterberg, L. 22:179

Whiteford, H.A. 21:1, 22:21
Wiedemann, K. 20:83
Wilcox, J.A. 21:303
Wilkinson, C.W. 21:313
Winokur, A. 20:325, 21:189
Wirz-Justice, A. 21:181
Witzke, W. 21:85
Wolfe, N. 20:107
Woods, D.J. 20:215
Wyatt, R.J. 22:291

Yamaguchi, T. 22:81
Yehuda, R. 20:129
Yeragani, V.K. 21:359, 22:37, 22:263
Yokoi, S. 21:285, 22:81
Yoshimoto, S. 21:229
Yuwiler, A. 22:283

Zeevi, S. 21:221
Zimmer, B. 21:111
Zimmerman, M. 20:265
Zureick, J.L. 22:99
Zwicker, A.P. 21:337



Subject Index for 1987

Adenosine

caffeine in plasma, anxiety, 21:247

Adenylate cyclase

lithium, platelet, 21:221

α_2 -Adrenoceptor

affective disorder, platelet, 22:127

affective illness, yohimbine in platelets,
20:107

panic disorder, rauwolscine binding,
22:43

β -Adrenoceptor

affective disorder, lymphocyte binding,
20:239

affective disorder, platelet, 22:127

leukocyte membrane, cyanopindolol,
22:265

schizophrenia, affective disorders, 22:265

Adrenocorticotrophic hormone

cortisol, affective illness, 20:325, 22:117

lactate induced panic, 21:23

Affective disorder

adrenal gland volume, computed tomography, 21:189

α_2 -adrenoceptor, platelets, 20:107, 22:127

β -adrenoceptor binding, dexamethasone
suppression test, 22:265

β -adrenoceptor binding, severity, 20:239,
22:127

adrenocorticotrophic hormone, dexamethasone suppression, 20:235, 22:117

amino acids in serum, dexamethasone
suppression test, 21:323

apomorphine, growth hormone, 22:193

arachidonic acid, platelet membrane
phospholipid incorporation, 22:275

arecoline infusion, sleep, 22:261

bipolar disorder, growth hormone
releasing factor, 22:141

bipolar disorder, growth hormone
response to clonidine, 22:193

bipolar disorder, sodium transport, 22:49

bipolar/unipolar, Minnesota Multiphasic
Personality Inventory, 22:159

bipolar/unipolar, norepinephrine, 21:161

bipolar/unipolar, panic attack incidence,
20:183

bipolar/unipolar, positron emission
tomography, 22:81

blood pressure, clonidine and apomorphine response, 22:193

Affective disorder (cont.)

blood pressure, endogenous subtype,
21:85

calcium in serum, anxiety, 22:29

carbamazepine, family history, 21:71

carbamazepine, sleep deprivation, 22:11

catecholamines, dexamethasone, 20:143,
22:21, 22:127

circadian rhythm, plasma 3-methoxy-4-
hydroxyphenylglycol, 20:79

clonidine, growth hormone, 22:193

corticotropin releasing hormone, affective
illness, 20:229

cortisol, catecholamines, 20:143, 22:21,
22:127

cortisol, electroconvulsive therapy and
naloxone, 22:207

cortisol, 3-methoxy-4-hydroxyphenylglycol,
22:127

cortisol, naloxone effect, 22:207

cortisol response to adrenocorticotrophic
hormone, 20:235, 22:117

cortisol, serum amino acids, 21:323

delusional depression, family study, 21:277

dementia, antidepressants, 21:111

depression assessment, comparison of five
self-report scales, 22:243

depression, Plutchik-van Praag self-report
scale, 22:243

dexamethasone, cortisol, 20:143, 22:21,
22:117

dexamethasone, β -endorphin, 21:151

dexamethasone in plasma, cortisol
suppression, 20:83

dexamethasone suppression test,
 β -adrenoceptor binding, 22:P\$

dexamethasone suppression test, adrenocorticotrophic hormone, 22:117

dexamethasone suppression test,
melancholic subgroups, 20:235

dexamethasone suppression test,
norepinephrine, 21:161

dexamethasone suppression test,
serum amino acids, 21:323

dexamethasone suppression, thyroid
stimulating hormone, 22:21, 22:127

dexamethasone suppression, urinary
catecholamines, 20:229

dopamine in plasma, psychotic depression,
20:143

Affective disorder (cont.)

- electroconvulsive therapy, carbamazepine, 22:11
- electroconvulsive therapy frequency, 21:63
- electroconvulsive therapy, naloxone neuroendocrine effect, 22:207
- electroconvulsive therapy, thyroid-stimulating hormone, 20:207
- emotional blunting, factor analytic study, 20:57
- β -endorphin, dexamethasone, 21:151
- familial subtypes, 3-methoxy-4-hydroxyphenylglycol, 22:117
- family history, carbamazepine response, 21:71
- fenfluramine response, prolactin 22:257
- frontal lobe, positron emission tomography, 22:81
- generalized anxiety disorder, mothers' illness, 20:285
- glucose in serum, anxiety, 22:29
- growth hormone, clonidine response, 22:193
- growth hormone, electroconvulsive therapy and naloxone, 22:207
- growth hormone releasing factor, lithium, 22:141
- head trauma, bipolar/depressive 21:303
- homovanillic acid, thyroid-stimulating hormone, 22:21
- hyperventilation, serum phosphate, 22:29
- hypothyroidism, depressive symptoms, 21:199
- imipramine binding, platelet, 21:33
- immune cell function, natural killer cell activity, 20:181
- light therapy, mood effect, 22:1
- lithium distribution, mania, 20:1
- lithium effect, sodium transport, 22:49
- lithium, growth hormone releasing factor, 22:141
- magnetic resonance imaging, bipolars, 21:357
- mania, growth hormone response to clonidine and apomorphine, 22:193
- membrane potential, lithium effect, 22:49
- 3-methoxy-4-hydroxyphenylglycol, circadian rhythm, 20:79
- 3-methoxy-4-hydroxyphenylglycol, panic attacks, 20:183
- 3-methoxy-4-hydroxyphenylglycol, thyroid-stimulating hormone, 22:21, 22:127

Affective disorder (cont.)

- Minnesota Multiphasic Personality Inventory, 22:159
 - monoamine metabolites, red blood cell/lithium ratio, 20:1
 - monoamine oxidase inhibitors, social behavior, 22:89
 - naloxone, electroconvulsive therapy, 22:207
 - norepinephrine, cold challenge, 21:161
 - norepinephrine in plasma, cortisol, 22:117
 - opioids, electroconvulsive therapy, 22:207
 - panic disorders, adolescents, 20:275
 - phosphate serum levels, anxiety, 22:29
 - phospholipids, arachidonic acid incorporation, 22:275
 - placebo response, antidepressants, 21:9
 - positron emission tomography, bipolar/unipolar, 22:81
 - prolactin, electroconvulsive therapy and naloxone, 22:207
 - prolactin response, fenfluramine, 22:257
 - psychotic depression, plasma dopamine, 20:143
 - secondary depression, thyroid-stimulating hormone, 22:21
 - self-report scales, development and methodology, 22:243
 - serotonin reuptake inhibitors, fenfluramine, 22:257
 - severity, β -adrenoceptor binding, 20:239
 - severity, dopamine in plasma, 20:143
 - severity, rapid eye movement sleep, 20:189
 - severity, thyroid-stimulating hormone, 22:21
 - sleep, arecoline infusion, 22:261
 - sleep deprivation, carbamazepine, 22:11
 - sleep deprivation, older endogenous depression, 21:95
 - sleep, frequency analysis of electroencephalogram, 21:89
 - sleep variables, polysomnography 20:189
 - sodium transport, lithium effect, 22:49
 - suicidal thoughts, 5-hydroxy-indoleacetic acid, 21:1
 - suicide, delusional depression, 21:277
 - thyroid-stimulating hormone, depressive symptoms, 21:199
 - thyroid-stimulating hormone, electroconvulsive therapy, 20:207
 - thyroid-stimulating hormone, 3-methoxy-4-hydroxyphenylglycol, 22:21
- Age
- α_2 -adrenoceptors in platelets, affective illness 20:107

- Age (cont.)
 anxiety, caffeine in plasma, 21:247
 cortisol, affective illness, 20:143, 20:155
 dopamine in plasma, affective illness, 20:143
 dopamine- β -hydroxylase, 20:221
 melatonin, chronic pain, 22:179
- Aggressive behavior
 amphetamine, laboratory response, 21:257
- Alcoholism
 perceptual aberration scale, monoamine oxidase, 20:129
 reaction time, evoked potentials, 22:B\$
 thyroid-stimulating hormone, secondary depression, 22:21
- Alzheimer's dementia
 antidepressant treatment, 21:111
 personality change, factor structure, 21:55
- Amino acids
 brains post-mortem, schizophrenia, 22:291
 dexamethasone suppression test, affective disorder, 21:323
 schizophrenia, levels in cerebrospinal fluid, 20:337
- Amphetamine
 aggressive behavior, button press response, 21:257
 psychosis induction, 5-hydroxytryptophan, 22:283
- Anorexia nervosa
 clonidine, growth hormone response, 20:19
 clonidine treatment, 3-methoxy-4-hydroxyphenylglycol, 20:249
 β -endorphin, desmethylinipramine response, 20:19
 rapid eye movement sleep, concurrent depression, 20:189
- Antidepressants
 carbamazepine response, sleep deprivation and electroconvulsive therapy, 22:11
 dementia treatment in elderly, 21:111
 lactate panic, hyperventilation 21:205
 monoamine oxidase inhibitors, social behavior, 22:89
 placebo response, 21:9
 sleep deprivation, prolactin and growth hormone, 21:337
 triiodothyronine potentiation, learned helplessness, 21:267
- Apomorphine
 growth hormone response, affective disorder, 22:193
- Arachidonic acid
 membrane phospholipids, schizophrenia, 22:275
- Arecoline
 rapid eye movement sleep, affective illness, 22:261
- Attention
 electroencephalogram, lithium, 20:117
 negative symptoms, schizophrenia, 20:47
- Blood pressure
 anorexia nervosa, clonidine, 20:19
 clonidine, anorexia nervosa, 20:249
 clonidine and apomorphine response, affective disorder, 22:193
 endogenous/nonendogenous diagnosis, 21:85
 lactate infusion, bulimia, 21:213
 lactate infusion, panic disorder, 21:169, 22:263
 mitral valve prolapse, panic disorder, 20:13
 panic disorder, plasma norepinephrine, 21:313
 schizophrenia, speaking, 22:69
- Blood-brain barrier
 dynamic computed tomography, schizophrenia, 22:229
- Borderline personality disorder
 prolactin, cortisol and T₃, 21:307
 thyroid-stimulating hormone, haloperidol treatment, 21:307
- Brain structure
 magnetic resonance imaging, schizophrenia, 20:33
- Brofaremine
 rapid eye movement sleep, 20:177
- Bromocriptine
 cocaine craving reversal, 20:261
- Bulimia. *See also* Anorexia nervosa
 lactate induced panic, 21:213
 sleep recording, depression type, 20:189
- Caffeine
 adenosine in plasma, anxiety, 21:247
- Calcium
 affective disorder, serum levels, 22:29
- Cancer
 monoamine oxidase in platelets, depression, 22:111
- Carbamazepine
 mania response, family history, 21:71
 response rate compared to sleep deprivation, 22:11

- Carbamazepine**
schizophrenia, clinical response, 22:D\$
- Carbidopa**
homovanillic acid, lack of effect, 21:185
- Carbon dioxide**
panic disorder, inhalation, 20:87
- Catecholamines**
corticotropin-releasing hormone, affective disorder, 20:229
depression severity, cerebrospinal fluid levels, 21:1
dexamethasone, affective illness, 20:143
growth hormone response to clonidine and apomorphine, 22:193
lithium treatment, red blood cell ratio, 20:1
monoamine oxidase, affective symptoms, 20:155
panic disorder, mitral valve prolapse, 20:13
- Childhood disorders**
generalized anxiety disorder, over-anxious disorder, 20:285
panic disorder, concurrent depression, 20:275
- Circadian rhythms**
light therapy, mood change, 22:1
3-methoxy-4-hydroxyphenylglycol, affective illness, 20:79
sleep phase shift, mood in normals, 22:149
- Circannual rhythm**
diurnal mood variation, 21:181
imipramine binding, affective disorder, 21:33
light therapy, seasonal affective disorder, 22:1
personality dimensions, 21:181
placebo response, antidepressants, 21:9
- Clonidine**
anorexia nervosa, growth hormone and desmethylinipramine, 20:19
anorexia nervosa, 3-methoxy-4-hydroxyphenylglycol, 20:249
growth hormone response, affective disorder, 22:193
- Cocaine**
bromocriptine reverses craving, 20:261
- Computed tomography**
adrenal gland volume, 21:189
blood-brain barrier, schizophrenia, 22:229
contrast material time-density curves, schizophrenia, 20:165
schizophrenia, third ventricle enlargement, 21:49
- Computed tomography (cont.)**
ventricular size, methodological review, 22:91
- Corticotropin releasing hormone**
norepinephrine, affective disorder, 20:229
- Cortisol**
 β -adrenoceptor binding, schizophrenia and affective disorder, 22:265
adrenocorticotrophic hormone effect, affective illness, 20:235, 22:117
affective illness, dexamethasone, 20:143, 20:155
amino acids in serum, affective illness, 21:323
anorexia nervosa, clonidine and desmethyl-imipramine, 20:19
borderline personality disorder, 21:307
 β -endorphin, dexamethasone, 21:151
lactate induced panic, 21:23
monoamine oxidase in platelet, 20:155
naloxone and electroconvulsive therapy, 22:207
norepinephrine, affective illness, 22:127
- Cyanopindolol**
leukocyte membrane binding, affective disorder and schizophrenia, 22:265
- Cyclic adenosine monophosphate**
lithium adenylate cyclase in platelet, 21:221
- Dementia**
antidepressant treatment in elderly, 21:111
- Desipramine**
anorexia nervosa, weight, 20:19
cortisol, clonidine, 20:19
growth hormone, β -endorphin, 20:19
sleep deprivation, prolactin and growth hormone, 21:337
- Dexamethasone**
adrenocorticotrophic hormone effect, cortisol, 20:235
cortisol suppression, plasma level, 20:83
- Dexamethasone suppression test**
 β -adrenoceptor binding, affective disorder, 20:239, 22:265
 β -adrenoceptor binding, schizophrenia, 22:265
adrenocorticotrophic hormone, affective illness, 22:117
amino acids in serum, affective disorder, 21:323
catecholamines in plasma, psychotic depression, 20:143
corticotropin-releasing hormone, norepinephrine, 20:229
cortisol, 3-methoxy-4-hydroxyphenylglycol, 22:127

- Dexamethasone suppression test (cont.)
 β -endorphin and β -lipotropin, cortisol, 21:151
 family history of affective illness, 20:265
 norepinephrine, cold challenge, 21:161
 thyroid-stimulating hormone, affective illness, 22:21
- Diagnosis
 Diagnostic Inventory Schedule for Children, 20:285
 generalized anxiety disorder, validity, 20:285
 Minnesota Multiphasic Personality Inventory, diagnostic validation, 22:159
 panic disorder and concurrent depression in adolescents, 20:275
- Dihydroalprenolol
 lymphocyte binding, affective disorder, 20:239
- Dopamine
 affective illness, dexamethasone, 20:143, 20:155
- Dopamine- β -hydroxylase
 schizophrenia, family study, 20:221
- Electroconvulsive therapy
 carbamazepine, sleep deprivation, 22:11
 dementia, 21:111
 naloxone, growth hormone and prolactin, 22:207
 prolactin and thyroid-stimulating hormone, 20:207
 treatment frequency, 21:63
- Electroencephalogram
 frequency analysis, sleep, 21:89
 lithium, normal controls, 20:117
 sleep, affective illness, 21:89
 ventricular enlargement, frequency analysis in schizophrenia, 21:137
- β -Endorphin
 anorexia nervosa, clonidine, 20:19
- Epinephrine
 affective illness, dexamethasone, 20:143, 20:155
 anxiety ratings, panic disorder, 21:313
- Evoked potentials
 contingent negative variation, schizophrenia and alcoholism, 22:331
 neuroleptic side effects, hemispheric asymmetry, 22:311
- Eye movements
 lateralization, schizophrenia, 20:215
 smooth pursuit, schizophrenia, 21:293
- Fenfluramine
 prolactin response, affective disorder, 22:257
- Frontal lobe
 amino acids, post-mortem brain in schizophrenia, 22:291
 blood-brain barrier permeability, hypo-frontal pattern, 22:229
 glucose metabolic rate, affective disorder, 22:81
- Generalized anxiety disorder
 diagnostic validity, family study, 20:285
- Genetics
 delusional depression, multifactorial inheritance, 21:277
 dexamethasone suppression, family history of affective illness, 20:265
 dopamine- β -hydroxylase, schizophrenia, families, 20:221
 generalized anxiety disorder, mother's illness, 20:285
 human leukocyte antigens, schizophrenia, 20:69
 3-methoxy-4-hydroxyphenylglycol, familial subtypes of affective illness, 22:117
- Glucose
 phosphate serum level, affective illness, 22:29
 positron emission tomography, affective disorder, 22:81
 positron emission tomography, schizophrenia, 21:285
 positron emission tomography, sex differences in metabolic rate, 21:237
- Growth hormone
 anorexia nervosa, clonidine and desmethyl-imipramine, 20:19
 clonidine and apomorphine response, affective disorder, 22:193
 naloxone and electroconvulsive therapy, 22:207
 sleep deprivation, desimipramine treatment, 21:337
- Growth hormone releasing factor
 bipolar affective disorder, lithium effect, 22:141
- Heart rate
 clonidine, anorexia nervosa, 20:249
 lactate infusion, panic disorder, 22:341
 mitral valve prolapse, panic disorder, 20:13
 panic disorder, plasma norepinephrine, 21:313
 schizophrenia, speaking, 22:69

- Heart rate (cont.)
 - sleep infusion of arecoline, affective illness, 22:261
- Hemispheric asymmetry (see Laterality)
- Homovanillic acid
 - carbidopa effect, normal controls, 21:185
 - depression, cerebrospinal fluid level, 21:1
 - diet and physical activity, 20:307
 - lithium distribution, mania, 20:1
 - smoking, normal controls, 20:307
 - thyroid stimulating hormone, affective illness, 22:21
- Human leukocyte antigens
 - schizophrenia, chromosome 6, 20:69
- 5-Hydroxyindoleacetic acid
 - brains of suicides, 21:355
 - depression, cerebrospinal fluid level, 21:1
 - lithium distribution, mania, 20:1
- 5-Hydroxytryptamine
 - brains of suicides, 21:355
- 5-Hydroxytryptophan
 - amphetamine induced psychosis, schizophrenia, 22:283
- Imipramine
 - obsessive-compulsive disorder treatment, 21:123
- Imipramine binding
 - affective illness and panic disorder, 21:33
 - brains of suicides, platelet binding, 21:355
 - circannual variation, 21:33
- Immune function
 - affective illness, natural killer cells, 20:181
- Isoproterenol
 - blood pressure, panic disorder, 22:263
- Lactate
 - adrenocorticotrophic hormone, cortisol, 21:23
 - antidepressants, panic, 21:205
 - blood pressure, panic disorder, 22:263
 - bulimia, anxiety, 21:213
 - gravity feed administration, 21:359
 - heart rate, panic disorder, 22:341
 - panic attacks, baseline blood pressure, 21:169
 - panic disorder, agoraphobia, 20:97
- Laterality
 - brains of suicides, serotonergic function, 21:355
 - clockwise circling, schizophrenia, 20:215
 - evoked potentials, neuroleptic side effects, 22:311
- Learned helplessness
 - triiodothyronine, antidepressant interaction, 21:267
- Life events
 - schizophrenia, relapse off medication, 22:221
- Light
 - treatment, depression change, 22:1
- β -lipotropin
 - dexamethasone, cortisol, 21:151
- Lithium
 - adenylate cyclase, platelet, 21:221
 - electroencephalogram, normals, 20:117
 - growth hormone releasing factor, bipolars, 22:141
 - neuroleptic levels in brain and plasma, 20:313
- Lithium (cont.)
 - red blood cell ratio, monoamine metabolites, 20:1
 - sodium transport, red blood cell, 22:49
- Magnetic resonance imaging
 - bipolar affective illness, subcortical signal hyperintensities, 21:357
 - schizophrenia, ventricular size and image intensity, 20:33
- Melatonin
 - pain syndromes, depressive symptoms, 22:179
- Membrane transport
 - sodium transport, bipolar affective disorder, 22:49
- Memory
 - electroconvulsive therapy, 21:63
- Metanephrine
 - lithium distribution, mania, 20:1
- 3-Methoxy-4-hydroxyphenylglycol
 - anorexia nervosa, clonidine treatment, 20:249
 - circadian rhythm, affective illness, 20:79
 - corticotropin-releasing hormone, dexamethasone suppression test, 20:229
 - cortisol, thyroid stimulating hormone, 22:127
 - depression, cerebrospinal fluid level, 21:1
 - lithium distribution, mania, 20:1
 - mitral valve prolapse, panic disorder, 20:13
 - panic attacks, depressed patients, 20:183
 - red blood cell/lithium ratio, mania, 20:1
 - thyroid-stimulating hormone, affective illness, 22:21
- Mitral valve prolapse
 - panic disorder, catecholamines, 20:13
- Moclobemide
 - tyramine-pressor response, clinical response, 22:213

- Monoamine oxidase**
 cancer, depression, 22:111
 Hamilton Rating Scale for Depression, items, 20:155
 mitral valve prolapse, panic disorder, 20:13
 panic disorder, platelets, 22:37
 paranoia, schizophrenia, 22:99
 psychosis proneness, college students, 20:129
 psychotic depression, plasma catecholamines, 20:155
 race, gender, 22:99
 schizophrenia, auditory hallucinations, 22:99
 schizophrenia, β -phenylethylamine, 21:229
 smoking, normals, 20:199
- Monoamine oxidase inhibition**
 rapid eye movement sleep, 20:177
 social behavior, affective illness, 22:89
 tyramine-pressor response, 22:213
- Naloxone**
 electroconvulsive therapy, growth hormone and prolactin, 22:207
- Neuroleptics**
 brain distribution, rat, 20:299
 brain and plasma levels, lithium effect, 20:313
 carbamazepine combined with haloperidol, 22:303
 dopamine- β -hydroxylase, dose, 20:221
 β -endorphin, dexamethasone, 21:151
 evoked potentials, lateralized side effects, 22:311
 lateralized side effects, evoked potential hemispheric asymmetry, 22:311
 life events, relapse, 22:221
 thyroid-stimulating hormone, borderline personality disorder, 21:307
- Norepinephrine**
 affective illness, dexamethasone, 20:143, 20:155
 cold challenge, affective illness, 21:161
 corticotropin releasing hormone, affective illness, 20:229
 cortisol, affective illness, 22:127
 isotope dilution kinetics, 21:313
 lithium distribution, mania, 20:1
- Normal values**
 adrenal gland volume, CT scan, 21:189
 amino acids, brains, 22:291
 arachidonic acid incorporation, platelet membrane phospholipids, 22:275
- Normal values (cont.)**
 cortisol, dexamethasone, 20:143
 cortisol, plasma, 22:127
 cortisol, plasma, clonidine response, 20:19
 dexamethasone suppression test, 20:265
 dopamine, plasma, dexamethasone, 20:143
 electroencephalogram, lithium, 20:117
 β -endorphin, β -lipotropin, plasma, 21:151
 β -endorphin, plasma, clonidine stimulation, 20:19
 epinephrine, dexamethasone, 20:143
 growth hormone, clonidine response, 20:19
 growth hormone releasing factor, cerebrospinal fluid, 22:141
 imipramine binding, platelet, 21:33
 melatonin, serum and urine, 22:179
 3-methoxy-4-hydroxyphenylglycol, plasma, 22:127
 monoamine oxidase, platelets, 20:129, 22:27, 22:99
 norepinephrine, dexamethasone, 20:143
 norepinephrine, plasma, 22:127
 rauwolscine binding in platelet, 22:43
 sleep, EEG frequency analysis, 21:89
 smooth pursuit eye movements, 21:293
 ventricular size, magnetic resonance imaging, 20:33
 yohimbine binding, platelet, 20:107
- Normetanephrine**
 corticotropin-releasing hormone, affective illness, 20:229
 lithium distribution, mania, 20:1
- Obsessive-compulsive disorder**
 birth order, family size 21:347
 imipramine response, 21:123
- Opioids**
 naloxone, electroconvulsive therapy, 22:207
- Outcome**
 emotional blunting, treatment response, 20:57
 red blood cell/lithium ratio, 20:1
- Pain syndromes**
 melatonin, neurogenic pain syndrome, 22:179
- Panic disorder**
 adolescents, concurrent depressive disorders, 20:275
 α_2 -adrenoceptor binding, platelet, 22:43
 adrenocorticotrophic hormone, lactate administration, 21:23

Panic disorder (cont.)

blood pressure, lactate panic, 21:169, 22:263

catecholamines, cardiovascular measures, 20:13

CO₂ inhalation, panic provocation, 20:87

cortisol, lactate effect, 21:23

epinephrine, anxiety ratings, 21:313

heart rate, lactate infusion, 22:341

lactate, blood pressure, 22:263

lactate infusion, 20:97

imipramine binding, platelet, 21:33

3-methoxy-4-hydroxyphenylglycol, depressed patients, 20:183

mitral valve prolapse, platelet monoamine oxidase, 20:13

monoamine oxidase in platelets, 22:37

norepinephrine kinetics, 21:313

psychoactive medication, lactate panic, 21:205

Phenylacetic acid

schizophrenia, monoamine oxidase, 21:229

 β -Phenylethylamine

schizophrenia, monoamine oxidase, 21:229

Phosphate

affective disorder, serum levels, 22:29

Phospholipids

arachidonic acid incorporation, platelet membranes, 22:275

Platelets

adenylate cyclase, lithium, 21:221

arachidonic acid incorporation, membrane phospholipids, 22:275

imipramine binding, affective illness, 21:33

monoamine oxidase, mitral valve prolapse, 20:13

monoamine oxidase, panic disorder, 22:37

monoamine oxidase, psychosis proneness, 20:129

monoamine oxidase, psychotic depression, 20:155

monoamine oxidase, schizophrenia, 21:229

rauwolscine binding, panic disorder, 22:43

serotonin uptake, rat strain differences, 22:61

yohimbine binding, affective disorder, 20:107

Positron emission tomography

bipolar and unipolar affective disorder, 22:81

Positron emission tomography (cont.)

schizophrenia, frontal and parietal lobes, 21:285

sex differences, glucose, metabolic rate, 21:237

Prolactin

borderline personality disorder, haloperidol, 21:307

electroconvulsive therapy and thyroid-stimulating hormone, 20:207

fenfluramine response, affective disorder, 22:257

naloxone, electroconvulsive therapy, 22:207

sleep deprivation, desipramine treatment, 21:337

Race

schizophrenia, auditory hallucinations, 22:99

Red blood cell

lithium ratio, monoamine metabolites, 20:1

Rapid eye movement sleep (see Sleep)

Rauwolscine

panic disorder, platelet binding, 22:43

Reaction time

cross-over effect, schizophrenia, 22:331

Red blood cell

sodium transport, lithium effect, 22:49

Scales

Acute Panic Inventory, lactate infusions, 20:97, 21:169, 21:205

Beck Depression Inventory, β -adrenoceptor, 20:239

Beck Depression Inventory, correlation with four self-report scales, 22:243

Beck Depression Inventory, obsessive-compulsive disorder, 21:123

Blessed Dementia, Alzheimer's dementia, 21:55

Blessed Dementia, antidepressant response, 21:111

Brief Psychiatric Rating Scale, carbamazepine response, 22:303

Brief Psychiatric Rating Scale, life events, 22:221

Brief Psychiatric Rating Scale, negative symptoms, 20:47

Center for Epidemiological Studies—Depression Questionnaire, correlation with four self-report scales, 22:243

Compulsive Activity Checklist, imipramine response, 21:123

Emotional Blunting Scale, schizophrenia and affective illness, 20:57

Folstein Mini-Mental, antidepressants in elderly, 21:111

Geriatric Depression Scale, hypothyroidism, 21:199

Scales (cont.)

- Hamilton Rating Scale for Anxiety, platelet monoamine oxidase, 22:111
- Hamilton Rating Scale for Depression, adolescent/panic disorder, 20:275
- Hamilton Rating Scale for Depression, α_2 -adrenoceptor affinity, 20:107
- Hamilton Rating Scale for Depression, β -adrenoceptor binding, 20:239
- Hamilton Rating Scale for Depression, cerebrospinal fluid amine metabolites, 21:1
- Hamilton Rating Scale for Depression, electroconvulsive therapy, 20:207
- Hamilton Rating Scale for Depression, light treatment, 22:1
- Hamilton Rating Scale for Depression, monoamine oxidase 20:155
- Hamilton Rating Scale for Depression, phosphate and calcium, 22:29
- Hamilton Rating Scale for Depression, rapid eye movement sleep, 20:189
- Hamilton Rating Scale for Depression, sleep deprivation, 21:95
- Hamilton Rating Scale for Depression, thyroid-stimulating hormone, 22:21
- Inpatient Multidimensional Rating Scale, carbamazepine response, 22:303
- Manic Diagnostic and Severity Scale, lithium, 20:1
- Maudsley Obsessional-Compulsive Inventory, 21:123
- Minnesota Multiphasic Personality Inventory, diagnostic validation, 22:159
- Minnesota Multiphasic Personality Inventory, serum phosphate, 22:29
- Minnesota Multiphasic Personality Inventory D Scale, correlation with four self-report scales, 22:243
- Montgomery-Asberg Depression Scale, platelet monoamine oxidase, 22:111
- Perceptual Aberration Scale, platelet monoamine oxidase, 20:129
- Physical Anhedonia Scale, platelet monoamine oxidase, 20:129
- Plutchik-van Praag Self-Report Depression Scale, criteria for depression, 22:293
- Profile of Mood States, sleep deprivation, 21:95
- Scale for Assessment of Negative Symptoms, redundant measures, 20:47

Scales (cont.)

- Spielberger Anxiety Rating, bulimia, 21:213
 - Spielberger Anxiety Rating, imipramine response, 21:123
 - Spielberger Anxiety Rating, plasma caffeine, 21:247
 - Stanford Sleepiness Scale, sleep deprivation, 22:149
 - Subjective Units of Disturbance, anxiety, 20:87
 - Wechsler Adult Intelligence Scale, ventricular enlargement, 21:137
 - Wechsler Rating Scale for Depression, 20:19
 - Zung Depression Scale, anorexia nervosa, 20:19
 - Zung Depression Scale, comparison with four self-report scales, 22:243
 - Zung Anxiety Rating, plasma caffeine, 21:247
- Schizophrenia
- β -adrenoceptor binding, dexamethasone suppression test, 22:265
 - affect in facial emotion, photo judgment, 20:317
 - amino acids, cerebrospinal fluid, 20:337
 - amino acids, post-mortem brain, 22:291
 - γ -aminobutyric acid (GABA), post-mortem brain, 22:291
 - amphetamine induction of psychosis, 5-hydroxytryptophan, 22:283
 - auditory hallucinations, platelet-monoamine oxidase, 22:99
 - blood-brain barrier permeability, dynamic computed tomography, 22:229
 - blood pressure, speaking, 22:69
 - carbamazepine, clinical response, 22:303
 - computed tomography, blood-brain barrier permeability, 22:229
 - computed tomography, contrast material time density curves, 20:165
 - computed tomography, methodology, 22:91
 - contingent negative variation, reaction time, 22:331
 - cross-over effect, evoked potentials, 22:331
 - deficit syndrome, neuropsychological impairment, 22:319
 - dexamethasone suppression test, β -adrenoceptor binding, 22:265
 - dopamine- β -hydroxylase, family studies, 20:221
 - educational level, deficit syndrome, 22:319
 - electroconvulsive therapy, thyroid-stimulating hormone, 20:207

Schizophrenia (cont.)

- electroencephalogram, ventricular enlargement, 21:137
- emotional blunting, factor analytic study, 20:57
- employment status, blood pressure, 22:69
- evoked potentials, hemispheric asymmetry, 22:311
- evoked potentials, reaction time, 22:331
- eye movements, lateralization, 20:215
- eye movements, ventricle size, 21:293
- facial emotion judgments, 20:317
- fibroblasts, growth and response to toxic oxygen metabolites, 21:43
- frontal lobe, blood-brain barrier permeability, 22:229
- frontal white matter, magnetic resonance image, 20:33
- hallucinations, platelet monoamine oxidase, 22:99
- head trauma history, 21:303
- heart rate, speaking, 22:69
- high risk sample, Minnesota Multiphasic Personality Inventory, 22:159
- human leukocyte antigens, chromosome 6, 20:69
- 5-hydroxytryptophan, amphetamine induction of psychosis, 22:283
- hypofrontality, dynamic computed tomography, 22:229
- hypofrontality, positron emission tomography, 21:285
- laterality, blood-brain barrier permeability, 22:229
- laterality, clockwise circling, 20:215
- lateralized neuroleptic side effects, evoked potentials, 22:311
- life events, relapse, 22:221
- Luria-Nebraska Neuropsychological Battery, ventricular enlargement, 21:137
- magnetic resonance imaging, image intensity, 20:33
- Minnesota Multiphasic Personality Inventory, diagnosis, 22:159
- monoamine oxidase in platelet, auditory hallucinations, 22:99
- monoamine oxidase in platelets, psychosis proneness, 20:129
- monoamine oxidase, urinary phenylethylamine, 21:229
- negative symptoms, neuropsychological impairment, 22:319
- negative symptom measurement, 20:47
- negative symptoms, ventricular enlargement, 21:137

Schizophrenia (cont.)

- neuroleptics, relapse and life events, 22:221
- neuropsychological impairment, deficit syndrome, 22:319
- paranoid type, phenylethylamine in urine, 21:229
- paranoid type, platelet monoamine oxidase, 22:99
- phenylacetic acid, platelet monoamine oxidase, 21:229
- phenylethylamine, platelet monoamine oxidase, 21:229
- positron emission tomography, 21:285
- prolactin, electroconvulsive therapy, 20:207
- race, platelet monoamine oxidase, 22:99
- reaction time cross-over effect, evoked potentials, 22:331
- relapse, life events, 22:221
- schizoaffective disorder diagnosis, high-risk sample, 22:159
- schizophreniform, arachidonic acid incorporation, 22:275
- serotonin, psychosis induction by amphetamine, 22:283
- sex differences, platelet monoamine oxidase, 22:99
- speaking, cardiovascular response, 22:69
- ventricular enlargement, smooth pursuit eye movements, 21:293
- ventricular enlargement, Wechsler Adult Intelligence Scale, 21:137
- ventricular size, 20:33, 21:49
- ventricular size, methodological review, 22:91
- tardive dyskinesia, evoked potentials, 22:311
- Seasonal affective disorder
 - light treatment, mood change in normals, 22:1
- Serotonin
 - amphetamine induced psychosis, 5-hydroxytryptophan, 22:283
 - platelet uptake, methods and rat-strain differences, 22:61
 - prolactin response to fenfluramine, affective disorder, 22:257
- Sex differences
 - dopamine- β -hydroxylase, schizophrenia, 20:221
 - lactate response, panic disorder, 22:341
 - glucose metabolic rate, positron emission tomography, 21:237
 - melatonin, chronic pain, 22:179
 - 3-methoxy-4-hydroxyphenylglycol, panic disorder, 20:13

Sex differences (cont.)

- monoamine oxidase in plasma, panic disorder, 20:13
- monoamine oxidase in platelets, panic disorder, 20:13
- monoamine oxidase, platelets, 20:129, 20:155, 20:199, 22:37, 22:99
- panic disorder, lactate response, 22:341

Sleep

- arecoline infusion, rapid eye movement sleep, 22:261
- carbamazepine response, 21:71, 22:11
- deprivation, carbamazepine effect, 22:11
- deprivation, desipramine effect, 21:337
- frequency analysis, affective illness, 21:89
- growth hormone, sleep deprivation, 21:337
- monoamine oxidase inhibition, rapid eye movements, 20:177
- phase shift, mood change in normals, 22:149
- prolactin, sleep deprivation, 21:337
- rapid eye movement sleep, acute sleep delay, 22:149
- sleep deprivation, endogenous depression, 21:95

Sodium transport

- lithium effect, bipolar affective disorder, 22:49

Substance abuse

- cocaine craving, bromocriptine, 20:261
- monoamine oxidase, perceptual aberration, 20:129
- paraphernalia, cocaine, 20:261

Tachycardia (see Heart rate)

Tardive dyskinesia

- lateralized neuroleptic side effects, evoked potentials, 22:311

Thyroid-stimulating hormone

- β -adrenoceptor binding, dexamethasone suppression, 20:239

Thyroid-stimulating hormone (cont.)

- catecholamines, affective illness, 22:127
- depressive symptoms, nursing home, 21:199
- 3-methoxy-4-hydroxyphenylglycol, affective illness, 22:21
- neuroleptic effect, borderline personality disorder, 21:307
- prolactin and electroconvulsive therapy, 20:207

Triiodothyronine

- antidepressant potentiation, rat learned helplessness, 21:267
- borderline personality disorder, neuroleptic effect, 21:307

Tyramine pressor response

- monoamine oxidase inhibitor, moclobemide, 22:213

Vanillylmandelic acid

- corticotropin-releasing hormone, affective illness, 20:229

Ventricular size

- computed tomographic measurement, 22:91
- negative symptoms, neuropsychological scores, 21:137
- schizophrenia, magnetic resonance imaging, 20:33
- schizophrenia, third ventricle, 21:49
- smooth pursuit eye movements, schizophrenia, 21:293

Weight

- anorexia nervosa, desmethyl-imipramine, 20:19
- clonidine, anorexia nervosa, 20:249
- growth hormone-releasing factor, cerebrospinal fluid, 22:141

Yohimbine

- affective disorder, platelet binding, 20:107